Table 1 Previously reported cases on the correlation between TEF and bevacizumab
Article | Age, sex | Tumor type | Treatment | Risk factors | Using time and dosage of Bev | Outcome |
|---|---|---|---|---|---|---|
Goodgame 2008 | 28, M | NSCLC | PTX + CBDCA + Bev → Bev | TRT | 2 Cycles, 21 days per 1 cycle; 15 mg/kg | NA |
Gore 2009 | 48, M | NSCLC | GEM + CBDCA + Bev → Bev | TRT | 1 Cycle; NA | NA |
Spigel 2010 | 62, F | NSCLC | PEM + CBDCA + Bev | TRT/esophagitis | 8 Cycles, 21 days per 1 cycle; 15 mg/kg | NA |
55, M | NSCLC | PEM + CBDCA + Bev | TRT/esophagitis | 10 Cycles, 21 days per 1 cycle; 15 mg/kg | NA | |
57, F | SCLC | CPT-11 + CBDCA + Bev | TRT/esophagitis | 16 Cycles, 14 days per 1 cycle; 10 mg/kg | NA | |
57, F | SCLC | CPT-11 + CBDCA + Bev | TRT/esophagitis | 10 Cycles, 14 days per 1 cycle; 10 mg/kg | Dead due to TEF | |
67, M | SCLC | CPT-11 + CBDCA + Bev | TRT/esophagitis | NA | NA | |
Socinski 2012 | NA | NSCLC | PEM + CBDCA + Bev | TRT | NA | NA |
Schreiber 2012 | 40, M | NSCLC | PEM + CBDCA + Bev | TRT/Barret’s esophagus | 1 Cycle; 7.5 mg/m2 | Dead due to hemoptysis |
Kenichi 2018 | 66, M | NSCLC | PEM + CBDCA + Bev | None | 1 Cycle; 15 mg/kg | Dead due to lung cancer |
Zhang 2020 | 54, M | NSCLC | PEM + CBDCA + Bev | TRT | 4 Cycles, 21 days for 1 cycle; 7.5 mg/kg | NA |